Pharma BD Deal Intelligence
Cephalon's $223M bet on Arana's biologics platform produced no approved drug — lead asset placulumab (ART621) was discontinued, and Cephalon itself was absorbed by Teva just two years after closing.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Cephalon to acquire Arana Therapeutics for A$1.40 cash per share (~A$318M / US$207M), a ~70% premium to the 90-day VWAP; Arana directors unanimously recommend…
Cephalon's filed takeover offer for Arana detailed cash consideration, conditional sweetener (additional AU$0.05/share at 90% acceptance), and the strategic…
Cephalon completed its AU$318M / ~$202.7M acquisition of Arana, gaining a domain-antibody anti-TNF (ART621) in Phase 2, plus a portfolio of inflammatory and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
AU$318M / ~$202.7M cash takeover offer for Australian biotech (anti-TNF, antibody platform). Closed Aug 10, 2009. Source: SEC, GenEngNews.
Cephalon's $223M bet on Arana's biologics platform produced no approved drug — lead asset placulumab (ART621) was discontinued, and Cephalon itself was absorbed by Teva just two years after closing.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Arana Therapeutics Limited (this deal) | 2009 | $203M | 22 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Cell Therapeutics, Inc. | 2005 | $70M | 74 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
← Browse all deals · How we score deals
More: 2009 deals · Cephalon Inc. deals